Fig. 3.
Actuarial probability of relapse after AML remission, comparing the 3 postremission regimens from CCG-2891.
Numbers are patients at risk at yearly intervals; rows are in the same order as curves. P value is for homogeneity. Dashed line indicates allogeneic BMT; solid line, intensive non–marrow-ablative chemotherapy; dotted line, autologous BMT.